Tempus AI Inc(TEM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.44 | Insider Own | 40.34% | Shs Outstand | 175.0M | Perf Week | -5.17% |
| Market Cap | 10.60B | Forward P/E | 1515.87 | EPS next Y | 117.99% | Insider Trans | -2.22% | Shs Float | 107.7M | Perf Month | 5.48% |
| Enterprise Value | 11.23B | PEG | - | EPS next Q | -0.08 | Inst Own | 56% | Short Float | 27.75% | Perf Quarter | 18.71% |
| Income | -0.25B | P/S | 7.4 | EPS this Y | 64.68% | Inst Trans | 4.53% | Short Ratio | 4.65 | Perf Half Y | 11.5% |
| Sales | 1.43B | P/B | 23.77 | EPS next 5Y | - | ROA | -12.75% | Short Interest | 29.87M | Perf YTD | -0.52% |
| Book/sh | 2.47 | P/C | 12.99 | EPS past 3/5Y | 10.57% 1.21% | ROE | -67.44% | 52W High | -43.69% ($104.32) | Perf Year | -24.85% |
| Cash/sh | 4.52 | P/FCF | - | Sales past 3/5Y | 58.29% 46.57% | ROIC | -13.56% | 52W Low | 44.08% ($40.77) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -21.05% | Gross Margin | 62.92% | Volatility(W/M) | 6.66% 7.35% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 7.84 | Sales Y/Y TTM | 50.43% | Oper. Margin | -18.92% | ATR (14) | 4.4 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.16 | EPS Q/Q | 112.51% | Profit Margin | -17.77% | RSI (14) | 47.86 | Recom | 2.23 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.3 | Sales Q/Q | 21.56% | SMA20 | -5.79% ($62.35) | Beta | 3.72 | Target Price | $66.94 |
| Payout | - | Debt/Eq | 3.25 | Earnings | 2026/7/30 | SMA50 | 5.03% ($55.93) | Rel Volume | 0.85 | Prev Close | $61.28 |
| Employees | 3800 | LT Debt/Eq | 3.22 | EPS/Sales Surpr. | 71.99% 0.74% | SMA200 | 4.29% ($56.32) | Avg Volume(3M) | 6.42M | Price | $58.74 |
| IPO | 2024/6/14 | Option/Short | Yes/Yes | Trades | 54275 | Volume | 5,456,395 | Change | -4.14% |
Company
TEM is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US precision medicine company that combines genetic testing, clinical data, and artificial intelligence to help diagnose and treat diseases such as cancer, the company is a precision medicine data and diagnostics business. It is growing rapidly on the back of its massive data assets but remains unprofitable.
Over the past 1 year, roughly in the middle
44% below its 1-year high.
TEM has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +64.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 56.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ARKG 0.09%
ARKK 0.05%
ULTI 0.05%
HEAL 0.04%
EKG 0.04%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
TEMT 35M
TEMC -It ranks #3 in the industry
Based on market cap of $11B.
TEM $11B PER -
VEEV $42B PER 42.9
BTSG $11B PER 43.2
HQY $8B PER 34.1
FAQ
What kind of company is TEM?
TEM belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of TEM?
The market cap of TEM is approximately $10.6B, ranking 904 within its sector.
What is the 52-week high and low for TEM?
TEM has recorded a 52-week high of $104.32 and a low of $40.77.
